9 things to know as AstraZeneca and J&J COVID-19 vaccines face safety scrutiny

14 Apr 2021

·www.massdevice.com

Vaccine

But the fate of adenovirus-vectored vaccines from AstraZeneca and Johnson & Johnson has become murky after a limited number of people receiving those vaccines have developed severe blood clot disorders. Officials in both the EU and the U.S. suspect there could be a link between adenovirus-based COVID-1 vaccines and blood clotting problems such as cerebral venous sinus thrombosis. Authorities in both countries have either temporarily halted or constrained the use of adenovirus vaccines. FDA anticipates that the pause in J&J vaccine use will last a matter of days. Get the full story from our sister site, Drug Discovery & Development.

Organizations

AstraZeneca PLC

Johnson & Johnson

Indications

ThrombosisSinus Thrombosis, Intracranial

Targets

Drugs

Adenovirus type 4 and type 7 vaccine(Emergent BioSolutions, Inc.)

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.